IGN — Inno-Gene SA Share Price
Last trade - 00:00- PLN10.23m
- PLN5.59m
- PLN1.13m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.55 | ||
| Price to Tang. Book | 1.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.13% | ||
| Return on Equity | -19.24% | ||
| Operating Margin | -203.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 1.36 | 4.68 | 29.88 | 16.29 | 1.13 | n/a | n/a | -16.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +290.42 | -94.63 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Inno-Gene SA is a Poland-based holding company engaged in management of a portfolio of companies active in life-science sector through the technology, research and development. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
Directors
- Jacek Wojciechowicz CMG
- Kamil Malek SEC
- Jerzy Born SUB
- Zbigniew Dembicki SUB
- Marcin Golebicki SUB
- Jakub Sitarz SUB
- Piotr Staniszewski SUB
- Dawid Sukacz SUB
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 10th, 2010
- Public Since
- February 8th, 2011
- No. of Employees
- 27
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Warsaw Stock Exchange
- Shares in Issue
- 5,701,081
- Address
- ul. Sciegiennego 20, POZNAN, 60-128
- Web
- http://www.inno-gene.pl/
- Phone
- +48 616468585
- Contact
- Marek Bugdol
- Auditors
- Moore Polska Audyt Sp z o.o.
Upcoming Events for IGN
Similar to IGN
Airway Medix SA
Warsaw Stock Exchange
Bioton SA
Warsaw Stock Exchange
Braster SA
Warsaw Stock Exchange
Captor Therapeutics SA
Warsaw Stock Exchange
E-Shopping SA
Warsaw Stock Exchange
FAQ
As of Today at 19:11 UTC, shares in Inno-Gene SA are trading at PLN1.80. This share price information is delayed by 15 minutes.
Shares in Inno-Gene SA last closed at PLN1.80 and the price had moved by -65.48% over the past 365 days. In terms of relative price strength the Inno-Gene SA share price has underperformed the FTSE Global All Cap Index by -67.59% over the past year.
The overall consensus recommendation for Inno-Gene SA is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
Inno-Gene SA does not currently pay a dividend.
Inno-Gene SA does not currently pay a dividend.
Inno-Gene SA does not currently pay a dividend.
To buy shares in Inno-Gene SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN1.80, shares in Inno-Gene SA had a market capitalisation of PLN10.23m.
Here are the trading details for Inno-Gene SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: IGN
Based on an overall assessment of its quality, value and momentum Inno-Gene SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inno-Gene SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -55.39%.
As of the last closing price of PLN1.80, shares in Inno-Gene SA were trading -46.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Inno-Gene SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN1.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Inno-Gene SA's management team is headed by:
- Jacek Wojciechowicz - CMG
- Kamil Malek - SEC
- Jerzy Born - SUB
- Zbigniew Dembicki - SUB
- Marcin Golebicki - SUB
- Jakub Sitarz - SUB
- Piotr Staniszewski - SUB
- Dawid Sukacz - SUB